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the CCEditorialThe present issue of the Journal displays eight papers
relating to cystic echinococcosis (CE) and alveolar echino-
coccosis (AE), 2 zoonotic diseases due to the infection by
cestodes of the Echinococcus genus, Helminths family. Echi-
nococcus spp. life cycle develops between carnivores, dogs
and other canids, as definitive hosts, which harbour the adult
tapeworm in their intestine, and herbivores for Echinococcus
granulosus sensu lato or small mammals for Echinococcus
multilocularis, as intermediate hosts where the larva (meta-
cestode) develops in different organs. Humans are dead-end
occasional hosts. Echinococcus spp. infection are still under-
reported and have received so far little attention from inter-
national public health institutions [1]. Echinococcus spp.-
related diseases can be described as chronic, complex and
neglected [2]. These characteristics derive from several inter-
related factors [3]: i) they are zoonoses with life cycles diffi-
cult to interrupt in the absence of sustained, expensive and
well-coordinated programs; ii) control of infection in
humans does not have impact on global infection spread;
however, echinococcosis is not perceived as an important
animal health problem, which impairs veterinary control
measures; iii) it is difficult to quantify echinococcosis burden
because of geographical distribution in vast rural areas,
absence of specific symptoms of most infected subjects, and
lack of an effective disease record system; and iv) these dis-
eases affect mostly poor pastoral communities. Echino-
coccosis/CE impact on human health is important, with
estimated 1.2 million people affected and 3.6 million DALYs
(Disability Adjusted Life Years) lost globally [1,3]. Moreover,
E. granulosus has major economic impact on agriculture with
estimated annual livestock production loss of up to 2190
million US$ [1]. Because of its severity and expensive care
management, AE, albeit rare, heavily impacts public health,
especially in China where at least 90% of world cases are
observed [4]. Definitely, Western China, including Xinjiang,
Ningxia and Tibet autonomous regions and Qinghai, Sichuan,
and Gansu provinces are among the most endemic areas in the
world for both CE and AE [5] and a national Chinese program
has been launched to combat the diseases [6]. Chinese refer-
ence centers, including their Radiology Departments, haveeview under responsibility of Beijing You'an Hospital affiliated to
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within the past 25 years, especially the newly designated
WHO-Collaborating Centre for Prevention and Care Man-
agement of Echinococcosis in Urumqi, Xinjiang Uyghur
Autonomous Region, which generated 6 among the 8 studies
on echinococcosis published in this issue. The worrisome
epidemiological status of China and the crucial role of
Imaging Units in the detection of suspicious images to both
improve the knowledge on incident cases and accelerate care
management of patients are well emphasized by the report of
Ding and Li in this issue [7]. With nearly 4000 incident cases
per year, China has definitely the highest prevalence rate of CE
in the world since a percentage of incident cases slightly lower
than in some other endemic countries is widely compensated
by the size of the at-risk population in China [8]. We may also
doubt that only 3 patients died from their disease in the 2011
to 2015 period [7]since AE as well as complication-associated
CE are very severe diseases with high fatality rate and we are
personally aware of far more fatalities in Western China
endemic areas in the past 5 years. This stresses the importance
of accurate reporting, especially for the follow-up of the
patients; currently, most of the patients (especially among the
nomadic populations) are lost to follow-up, and recording of
cases at the international level is clearly inaccurate and should
be improved (see discussion on this issue in Vuitton et al.,
2015, regarding AE in Europe) [9].
Despite their apparent similarity, CE and AE are quite
different diseases, CE being usually considered to present and
develop as a benign tumour and AE as a malignant tumour
[10]. Although it is usually true, CE may also display exten-
sive and multifocal locations and life-threatening complica-
tions. The paper by Fuhrer and Grohowski [11] is a good
illustration of the possible severity of CE when the cyst rup-
tures in the biliary tree, and their description of the ’string of
pearls‘ sign in the bile ducts, due to the migration of daughter
cysts in the biliary tree, certainly deserves radiologists’
attention. Unusual features of CE at CT and MRI in the liver
are also reported by Wang and Liu in this issue [12]: they may
be source of radiological misdiagnosis or misclassification,
e.g. because of an unusual location that could be confusing, or
because of failure of CT to characterize daughter cysts or
calcifications. It may be reminded that CT is usually good at. Production and hosting by Elsevier B.V. This is an open access article under
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degenerating CE; MRI is unable to do so but may reproduce
characteristic features of CE better than CT [13], and provide
pathognomonic evidence for the diagnosis of active AE by
showing hyperintense micro-cysts in a ‘honeycomb’ or ‘bunch
of grapes’ pattern on T2-weighted sequences [14]. Severity of
AE is mostly associated with invasion of hepatic vessels and
bile ducts, but also, like cancers, with metastatic dissemination
[10]. Brain metastases are rare in Europe (only 3 cases among
329 cases with hepatic AE in France [15]) but more frequent
in China (2 cases among 50 surgical cases with hepatic AE in
Xinjiang [16]). Differential imaging diagnosis of cerebral AE
is not easy: information provided by MR diffusion weighted
imaging reported in this issue [17] is an interesting comple-
ment that may help differentiate AE brain location from cer-
ebral tuberculosis, usually difficult since conventional MRI
features of both diseases are very similar.
AE diagnosis relies on imaging [14], and may be totally
confirmed only by pathological or molecular identification of
the parasite in the lesion [10]. Specific serology, i.e. presence of
specific antibodies against E. multilocularis, even when the best
antigens and techniques are used, may be positive in subjects
without lesions in endemic areas, and may be negative in
patients with confirmed AE, especially when they are immu-
nosuppressed [18]. At this point, the main 2 issues are: 1)
positive and differential diagnosis, 2) follow-up of the patients,
and especially evaluation of the viability of the parasitic larva
and of the progression potential of the lesion. The first issue is
problematic when the imaging characteristics of the lesions are
not recognized by radiologists and physicians, especially in
non-endemic areas, which may considerably delay diagnosis
and thus proper treatment [19]. The second issue is even more
problematic, since all markers of parasite viability are only
indirect, including fluoro-deoxyglucose Positron Emission
Tomography (FDG-PET), currently the most reliable indicator
of lesion metabolic activity [20]. FDG-PET as well as highly
specific serology (such as Em18 or Em2PLUS ELISA) actually
explore the activity of the associated immune reaction [21];
however, we showed that FDG uptake at the periphery of the
lesion was significantly correlated to the presence of the para-
sitic micro-cysts inside the lesion shown by T2-weighted MR
images [22]. As PET is not available in all settings, especially in
the most endemic areas, and its cost is an obstacle to its wide
use for the follow-up of the patients, in this issue, Wenya Liu
and her co-workers from the Xinjiang radiology team explore
surrogate imaging markers of disease progression/parasite via-
bility [23,24]. Results are quite encouraging, and the correlation
between iodine values obtained at spectral CT and SUVmax
obtained at FDG-PET was very significant, especially at the
portal phase. It may be noted that this correlation only con-
cerned the marginal zone of the lesions, a zone which combines
infiltration by immune cells (explored by FDG-PET) and neo-
vascularization (explored by enhanced conventional CT, spec-
tral CT and also by CEUS). The zone of the AE lesions where
measurements are performed is thus of utmost importance: this
is emphasized by the comparison between cholangiocarcinoma
and AE also published in this issue [25]. To differentiate AEfrom cancer, the ‘region of interest’ was defined as the solid
portion of the lesion, and only tumour-like type 4 AE lesions
were selected for the comparison; the lower mean Apparent
Diffusion Coefficient (ADC) of cholangiocarcinoma was due to
its relative tissue cellularity higher than that of AE [25]. Use of
diffusion weighted MRI to evaluate lesion activity in AE would
need measurement in the marginal zone of the lesion, where it
would appreciate the cellularity of the immune cell infiltration
which surrounds the parasitic lesion, that same area where
immune cells do uptake FDG and where neo-vessels were
responsible for increased iodine concentration in the studies by
Wang et al. and Jiang et al. [23,24].
AE is a severe disease still in search of an optimal treat-
ment, despite active research [26]. Experimental studies are
impaired by the rather long pre-patent infection (ranging from
2 to 6 months, depending on the species of experimental
rodents) and necessary autopsies of hundreds of animals.
Evaluating the feasibility and usefulness of ultrasound
examination of E. multilocularis-infected rats at the early
stages of development of the metacestode is particularly
interesting. The study performed by Zeng et al. [27] demon-
strates that lesions as small as 1 or 2 mm in diameter can
accurately be disclosed and these early lesions are hyper-
echoic, which confirms findings obtained from early lesions in
humans at mass screening [28] or in patients with immune
suppression [18]. For ethical as well as scientific reasons, non-
invasive imaging evaluation of the parasitic growth in small
animal models is a step forward to easier pre-clinical research
and wider use of US should be recommended to laboratories
actively involved in drug- or vaccine research.References
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